|
|
Дата |
|---|
| 23:08 |
| 16.11.2026 |
| 13.11.2026 |
| 12.11.2026 |
| 11.11.2026 |
| 10.11.2026 |
| 09.11.2026 |
| 06.11.2026 |
| 05.11.2026 |
| 04.11.2026 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
|---|---|---|---|---|---|---|---|
|
14.60
|
14.75
|
12.70
|
12.215
|
14.645
|
14.645
|
|
|
571 022.17
|
432.00
|
|
11.87
|
12.14
|
12.64
|
11.37
|
12.85
|
11.8676
|
|
|
592 276.75
|
662.00
|
|
12.64
|
13.00
|
14.70
|
12.80
|
14.70
|
13.08
|
|
|
435 002.47
|
708.00
|
|
14.50
|
15.13
|
15.30
|
14.08
|
15.30
|
14.96
|
|
|
1 382 159.83
|
548.00
|
|
14.82
|
16.46
|
14.72
|
13.96
|
15.705
|
15.385
|
|
|
496 900.94
|
524.00
|
|
15.00
|
15.19
|
14.04
|
12.82
|
15.01
|
14.78
|
|
|
1 077 624.85
|
1 279.00
|
|
16.07
|
16.93
|
10.10
|
9.92
|
13.47
|
13.30
|
|
|
901 734.48
|
1 107.00
|
|
10.00
|
10.48
|
11.60
|
9.705
|
11.60
|
10.145
|
|
|
707 974.94
|
847.00
|
|
10.14
|
12.15
|
13.225
|
10.56
|
13.225
|
11.61
|
|
|
841 809.02
|
800.00
|
|
13.23
|
14.17
|
13.80
|
13.20
|
13.93
|
13.48
|
|
|
365 088.76
|
303.00
|
Iambic Therapeutics, Inc. is a technology and clinical-stage life sciences company. Its molecular superintelligence platform integrates proprietary AI technologies with automated, scalable chemistry and biology experimentation. Its pipeline of drug candidates is developed using a molecular superintelligence platform. IAM1363, is a HER2 inhibitor that is in a Phase I/Ib clinical trial in subjects with HER2-altered solid tumors. The Company's additional programs, IAM217 (KIF18A inhibitor) and IAM-C1 (dual CDK2/4 inhibitor), are in preclinical development. IAM1363 is an oral, selective, pan-mutant, and brain-penetrant small molecule inhibitor that selectively targets HER2 and HER2 mutants, while sparing EGFR.
Amplification and mutations of HER2 drive a wide range of human cancers. IAM-C1 is a small-molecule inhibitor with a differentiated selectivity profile, designed to specifically target CDK2 and CDK4, two cell-cycle kinases that are frequently dysregulated in various cancers.
Показать все Скрыть